These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24196656)

  • 1. Cytochrome P450 2D6 poor metabolism, curvilinearity, and response: an intriguing observation requiring integration of psychopharmacology into pharmacogenetics.
    Al Hadithy AF; Birkenhager TK; Koch BC
    J Clin Psychopharmacol; 2013 Dec; 33(6):833-4. PubMed ID: 24196656
    [No Abstract]   [Full Text] [Related]  

  • 2. CYP 2D6 PM status and antidepressant response to nortriptyline and venlafaxine: is it more than just drug metabolism?
    Macaluso M; Preskorn SH
    J Clin Psychopharmacol; 2011 Apr; 31(2):143-5. PubMed ID: 21346604
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: no evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Gillman PK
    Hum Psychopharmacol; 2005 Jan; 20(1):61-2; author reply 63-4. PubMed ID: 15614840
    [No Abstract]   [Full Text] [Related]  

  • 4. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes.
    Olesen OV; Linnet K
    Drug Metab Dispos; 1997 Jun; 25(6):740-4. PubMed ID: 9193876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant drugs in the elderly--role of the cytochrome P450 2D6.
    Vandel P
    World J Biol Psychiatry; 2003 Apr; 4(2):74-80. PubMed ID: 12692778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
    Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
    J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?
    Haffen E; Vandel P; Paintaud G; Broly F; Vandel S; Bonin B; Bizouard P; Sechter D; Bechtel PR
    Eur J Clin Pharmacol; 2000; 55(11-12):877-9. PubMed ID: 10805068
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects and cost-effectiveness of pharmacogenetic screening for CYP2D6 among older adults starting therapy with nortriptyline or venlafaxine: study protocol for a pragmatic randomized controlled trial (CYSCEtrial).
    Berm EJ; Hak E; Postma M; Boshuisen M; Breuning L; Brouwers JR; Dhondt T; Jansen PA; Kok RM; Maring JG; van Marum R; Mulder H; Voshaar RC; Risselada AJ; Venema H; Vleugel L; Wilffert B
    Trials; 2015 Jan; 16():37. PubMed ID: 25636328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2D6 polymorphism and its impact on decision-making in psychopharmacotherapy: finding the right way in an ultrarapid metabolizing patient.
    Paulzen M; Tauber SC; Kirner-Veselinovic A; Gründer G
    J Clin Psychiatry; 2011 Nov; 72(11):1465-7. PubMed ID: 22127193
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6.
    Sánchez-Martín A; Sánchez-Iglesias S; García-Berrocal B; Lorenzo C; Gaedigk A; Isidoro-García M
    Pharmacogenomics; 2016 Aug; 17(12):1291-3. PubMed ID: 27469479
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
    Preskorn SH
    J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenoconversion of cytochrome P450 2D6: the need for identifying the intermediate metabolizer genotype.
    Berm EJ; Risselada AJ; Mulder H; Hak E; Wilffert B
    J Clin Psychiatry; 2013 Oct; 74(10):1025. PubMed ID: 24229757
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetic interaction between nortriptyline and terbinafine.
    Van Der Kuy PH; Van Den Heuvel HA; Kempen RW; Vanmolkot LM
    Ann Pharmacother; 2002 Nov; 36(11):1712-4. PubMed ID: 12398564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe adverse drug events under combination of nortriptyline and melperone due to pharmacokinetic interaction.
    Hefner G; Geschke K; Hiemke C
    J Clin Psychopharmacol; 2014 Jun; 34(3):394-6. PubMed ID: 24743723
    [No Abstract]   [Full Text] [Related]  

  • 17. Antidepressant treatment and altered CYP2D6 activity: are pharmacokinetic variations clinically relevant?
    D'Empaire I; Guico-Pabia CJ; Preskorn SH
    J Psychiatr Pract; 2011 Sep; 17(5):330-9. PubMed ID: 21926528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationship of therapeutic response to antidepressant plasma levels: an update.
    Friedel RO
    J Clin Psychiatry; 1982 Nov; 43(11 Pt 2):37-43. PubMed ID: 7174630
    [No Abstract]   [Full Text] [Related]  

  • 20. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
    Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
    J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.